17 June 2015

Director Dealings

VERONA PHARMA PLC - Director Dealings

PR Newswire

Verona Pharma plc

(“Verona Pharma” or the “Company”)

Director Dealings

17 June 2015, Cardiff – Verona Pharma plc (AIM: VRP) today received notification that on 17 June 2015 David Ebsworth, Director of the Company, purchased 250,000 ordinary shares of 0.1 pence each of the Company (“Ordinary Shares”) at a price of 4.7 pence per Ordinary Share.

Following the transaction David Ebsworth has a total interest of 3,829,774 Ordinary Shares, representing 0.38% of the total voting rights.

-Ends-

For further information please contact:

Verona Pharma plc                      Tel: +44 (0) 20 3283 4200           
Jan-Anders Karlsson, CEO                                                    
                                                                           
N+1 Singer                             Tel: +44 (0)20 7496 3000               
Aubrey Powell / Jen Boorer                                                  
                                                                           
FTI Consulting                         Tel: +44 (0)20 3727 1000             
Julia Phillips / Simon Conway                


Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us